Hereditary angioedema (HAE) is a rare genetic disorder that causes episodes of severe swelling throughout your body. It is caused by abnormal immune responses. But unlike allergic swelling ...

It is the first pre-filled pen presentation of Andembry, intended for once-monthly SC administration for the disease’s long ... the key initiator of HAE attacks. "With its novel mechanism ...

Hereditary Angioedema (HAE), a rare disease, which often remains undiagnosed due to its symptoms being similar to allergies, is a cause of concern as it can prove fatal, health experts at the Post ...

12 As with other diseases that are characterized by acute attacks, such as asthma, the burden of HAE is not only economic but also impacts the patient’s quality of life, education, relationships ...

Shire noted that the study was representative of the full HAE disease spectrum. Overall, 52% of the study’s 125 patients experienced three or more attacks per month at baseline, 65% of patients ...

The placebo control of the ALPHA-ORBIT trial should clarify if these attack-free rates are valid, but HAE is a highly individual disease. Any deviation from prior efficacy benchmarks would erode ...

HAE is estimated to affect more than 20,000 people ... medicine that has not been approved for the treatment of any disease by regulatory authorities. This press release includes forward-looking ...

CSL's head of R&D, Paul Mezzanotte, said that Andembry offers "a patient-centric, convenient administration method" that will help HAE patients achieve "long-term control over their disease." ...

CARLSBAD, Calif., February 20, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus ...